Edna Cukierman

Fox Chase Cancer Center — United States

Medicine · Health Sciences

50h-index18.0kcitations330works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(67), Cellular Mechanics and Interactions(54), Pancreatic and Hepatic Oncology Research(38), Cancer, Stress, Anesthesia, and Immune Response(38), Skin Protection and Aging(35)

Publications330 total

Supplementary Figures 1-6 from Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells
2025Open Access
Supplementary Table 1 from Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells
2025Open Access
Supplementary Figure S4 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S14 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S5 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S2 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S9 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Figure S2 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S1 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Figure S3 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S11 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S4 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Figure S1 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S13 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S10 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Figure S6 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S7 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Figure S5 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S12 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
Supplementary Table S8 from Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Kenneth M. Yamada(13), Janusz Franco‐Barraza(13), Roumen Pankov(6), Andres J. Klein–Szanto(6), Neelima Shah(5), Kazue Matsumoto(4), Ruchi Malik(4), Igor Astsaturov(3), Meenhard Herlyn(3), Vivek B. Shenoy(3), Miriam Rotman(3), Dan Cassel(3), Matthildi Valianou(3), Dorothy A. Beacham(3), Michael Amatangelo(3), Ralph Francescone(3), Erica A. Golemis(3), Remedios Castelló-Cros(3), Bruce J. Baum(3), Sunil R. Hingorani(2)